LivaNova (NASDAQ:LIVN) Director Sells 3,500 Shares of Stock

LivaNova PLC (NASDAQ:LIVN) Director Francesco Bianchi sold 3,500 shares of LivaNova stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $78.01, for a total transaction of $273,035.00. Following the transaction, the director directly owned 4,434 shares in the company, valued at approximately $345,896.34. The trade was a 44.11% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Francesco Bianchi also recently made the following trade(s):

• On Monday, August 31st, Francesco Bianchi sold 1,650 shares of LivaNova stock. The stock was sold at an average price of $79.72, for a total value of $131,538.00.

LivaNova Stock Up 3.1%

NASDAQ LIVN traded up $2.45 during midday trading on Monday, hitting $80.63. 551,807 shares of the company traded hands, compared to its average volume of 750,927. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.21. The company has a market cap of $4.44 billion, a PE ratio of 23.86 and a beta of 0.87. The company’s 50-day simple moving average is $80.35 and its 200-day simple moving average is $73.36. LivaNova PLC has a 52 week low of $48.82 and a 52 week high of $85.76.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.26 EPS for the quarter, topping the consensus estimate of $1.09 by $0.17. The firm had revenue of $390.59 million during the quarter, compared to analyst estimates of $380.50 million. LivaNova had a return on equity of 16.35% and a net margin of 12.82%.The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.05 EPS. As a group, equities research analysts forecast that LivaNova PLC will post 3.77 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on LIVN. Stifel Nicolaus set a $85.00 target price on shares of LivaNova in a report on Wednesday, August 5th. Freedom Capital raised shares of LivaNova to a “hold” rating in a research report on Tuesday, June 30th. Needham & Company LLC boosted their price objective on shares of LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings upgraded shares of LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, August 18th. Finally, Piper Sandler reissued an “overweight” rating and set a $90.00 target price (up from $87.00) on shares of LivaNova in a research report on Wednesday, September 2nd. Six research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, LivaNova presently has a consensus rating of “Moderate Buy” and an average target price of $84.12.

Institutional Trading of LivaNova

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tidal Investments LLC acquired a new position in shares of LivaNova in the second quarter valued at about $204,000. WINTON GROUP Ltd acquired a new stake in shares of LivaNova during the second quarter worth about $4,824,000. Integrated Wealth Concepts LLC acquired a new stake in shares of LivaNova during the second quarter worth about $119,000. Squarepoint Ops LLC purchased a new stake in LivaNova in the second quarter valued at approximately $1,418,000. Finally, Allworth Financial LP boosted its position in LivaNova by 93.5% in the second quarter. Allworth Financial LP now owns 298 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and manufactures technologies for the treatment of neurological and cardiovascular conditions. The company serves hospitals, physicians and patients in markets around the world, with operations and commercial activities spanning North America, Europe and other international markets.

LivaNova’s Neuromodulation business produces vagus nerve stimulation (VNS) systems marketed under the VNS Therapy brand. These implantable devices are used as an adjunctive treatment for drug-resistant epilepsy and are designed to deliver programmed electrical stimulation to the vagus nerve.